share_log

Leerink Partners Initiates Coverage On Regulus Therapeutics With Outperform Rating, Announces Price Target of $6

Moomoo 24/7 ·  Mar 18 08:25

Leerink Partners analyst Joseph Schwartz initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Outperform rating and announces Price Target of $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment